AAAAAA

   
Results: 1-25 | 26-28
Results: 1-25/28
DISTRIBUTION OF MOBILIZED PROGENITOR CELLS IN THE BUFFY COAT OF THE HEMONETICS MCS3P CELL SEPARATOR - A STUDY TO OPTIMIZE THE COLLECTION OFPROGENITORS BY LEUKAPHERESIS
Authors: GHIELMINI M PFISTER U ZUCCA E VANDENBOSCH S TAMASY P MARANGONI G BERTOLI G DERIVAZ JL CAVALLI F
Citation: M. Ghielmini et al., DISTRIBUTION OF MOBILIZED PROGENITOR CELLS IN THE BUFFY COAT OF THE HEMONETICS MCS3P CELL SEPARATOR - A STUDY TO OPTIMIZE THE COLLECTION OFPROGENITORS BY LEUKAPHERESIS, Journal of hematotherapy, 7(3), 1998, pp. 251-256
IN-VITRO SCHEDULE-DEPENDENCY OF MYELOTOXICITY AND CYTOTOXICITY OF ECTEINASCIDIN 743 (ET-743)
Authors: GHIELMINI M COLLI E ERBA E BERGAMASCHI D PAMPALLONA S JIMENO J FAIRCLOTH G SESSA C
Citation: M. Ghielmini et al., IN-VITRO SCHEDULE-DEPENDENCY OF MYELOTOXICITY AND CYTOTOXICITY OF ECTEINASCIDIN 743 (ET-743), Annals of oncology, 9(9), 1998, pp. 989-993
PREDICTING HEMATOLOGICAL TOXICITY (MYELOSUPPRESSION) OF CYTOTOXIC DRUG-THERAPY FROM IN-VITRO TESTS
Authors: PARCHMENT RE GORDON M GRIESHABER CK SESSA C VOLPE D GHIELMINI M
Citation: Re. Parchment et al., PREDICTING HEMATOLOGICAL TOXICITY (MYELOSUPPRESSION) OF CYTOTOXIC DRUG-THERAPY FROM IN-VITRO TESTS, Annals of oncology, 9(4), 1998, pp. 357-364
VENTRICULAR DIASTOLIC FUNCTION CHANGES IN PATIENTS WITH LYMPHOMA UNDERGOING HIGH-DOSE SEQUENTIAL CHEMOTHERAPY AND STEM-CELL TRANSPLANTATION
Authors: ZAPPA F GHIELMINI M CORTI R CAVALLI F GALLINO A
Citation: F. Zappa et al., VENTRICULAR DIASTOLIC FUNCTION CHANGES IN PATIENTS WITH LYMPHOMA UNDERGOING HIGH-DOSE SEQUENTIAL CHEMOTHERAPY AND STEM-CELL TRANSPLANTATION, Annals of oncology, 9, 1998, pp. 533-533
EVALUATION OF THE HEMATOTOXIC POTENTIAL OF METHOXYMORPHOLINYL-DOXORUBICIN (MMDX) METABOLITES IN PATIENTS PLASMA BY CLONOGENIC ASSAYS ON HEMATOPOIETIC PROGENITOR CELLS
Authors: GHIELMINI M COLLI E BOSSHARD G ZUCCHETTI M DINCALCI M GERONI C SESSA C
Citation: M. Ghielmini et al., EVALUATION OF THE HEMATOTOXIC POTENTIAL OF METHOXYMORPHOLINYL-DOXORUBICIN (MMDX) METABOLITES IN PATIENTS PLASMA BY CLONOGENIC ASSAYS ON HEMATOPOIETIC PROGENITOR CELLS, Annals of oncology, 9, 1998, pp. 206-206
PHASE-I CLINICAL AND PHARMACOKINETIC (PK) STUDY OF ORAL (PO) METHOXY-MORPHOLINO DOXORUBICIN (PNU-152243) ON A SINGLE INTERMITTENT SCHEDULE
Authors: SESSA C ZUCCHETTI M BAUER J NAEGELE H DINCALCI M GHIELMINI M ROSSI S VANDENBULCKE T PACCIARINI M DOMENIGONI L CAVALLI F
Citation: C. Sessa et al., PHASE-I CLINICAL AND PHARMACOKINETIC (PK) STUDY OF ORAL (PO) METHOXY-MORPHOLINO DOXORUBICIN (PNU-152243) ON A SINGLE INTERMITTENT SCHEDULE, Annals of oncology, 9, 1998, pp. 450-450
IN-VITRO CYTOTOXICITY OF ECTEINASCIDIN-743 (ET-743) AGAINST HUMAN HEMATOPOIETIC PROGENITORS AND CANCER-CELLS
Authors: GHIELMINI M COLLI E ERBA E BERGAMOSCHI D JIMENO J FAIRCLOTH G SESSA C
Citation: M. Ghielmini et al., IN-VITRO CYTOTOXICITY OF ECTEINASCIDIN-743 (ET-743) AGAINST HUMAN HEMATOPOIETIC PROGENITORS AND CANCER-CELLS, Annals of oncology, 9, 1998, pp. 533-533
HEMATOTOXICITY ON HUMAN BONE MARROW-DERIVED AND UMBILICAL-CORD BLOOD-DERIVED PROGENITOR CELLS AND IN-VITRO THERAPEUTIC INDEX OF METHOXYMORPHOLINYLDOXORUBICIN AND ITS METABOLITES
Authors: GHIELMINI M COLLI E BOSSHARD G PENNELLA G GERONI C TORRI V DINCALCI M CAVALLI F SESSA C
Citation: M. Ghielmini et al., HEMATOTOXICITY ON HUMAN BONE MARROW-DERIVED AND UMBILICAL-CORD BLOOD-DERIVED PROGENITOR CELLS AND IN-VITRO THERAPEUTIC INDEX OF METHOXYMORPHOLINYLDOXORUBICIN AND ITS METABOLITES, Cancer chemotherapy and pharmacology, 42(3), 1998, pp. 235-240
INHIBITION OF CFU-GM GROWTH BY IDARUBICINOL CONTAINING PLASMA SAMPLESOBTAINED FROM POOR-PROGNOSIS LYMPHOMA PATIENTS TREATED WITH 3-DAYS INFUSION IDARUBICIN
Authors: CORSINI C MANCUSO P GHIELMINI M ZUCCHETTI M TEALDO F COCOROCCHIO E FERRUCCI PF PECCATORI F DINCALCI M MARTINELLI G
Citation: C. Corsini et al., INHIBITION OF CFU-GM GROWTH BY IDARUBICINOL CONTAINING PLASMA SAMPLESOBTAINED FROM POOR-PROGNOSIS LYMPHOMA PATIENTS TREATED WITH 3-DAYS INFUSION IDARUBICIN, Experimental hematology, 26(8), 1998, pp. 378-378
INTRAPATIENT COMPARISON OF AN INTERMITTENT AND A CONTINOUS FLOW CELL SEPARATOR FOR THE COLLECTION OF PROGENITOR AND STEM-CELLS FROM THE BLOOD
Authors: BERETTA F VANDENBOSCH S CASTELLI D CAVALLI F GHIELMINI M
Citation: F. Beretta et al., INTRAPATIENT COMPARISON OF AN INTERMITTENT AND A CONTINOUS FLOW CELL SEPARATOR FOR THE COLLECTION OF PROGENITOR AND STEM-CELLS FROM THE BLOOD, Vox sanguinis, 75(2), 1998, pp. 149-153
HIGH-DOSE SEQUENTIAL CHEMOTHERAPY WITH AUTOLOGOUS BLOOD STEM-CELL RESCUE FOR RELAPSED OR RESISTANT LYMPHOMA
Authors: SANNA P VANDENBOSCH S CAVALLI F GHIELMINI M
Citation: P. Sanna et al., HIGH-DOSE SEQUENTIAL CHEMOTHERAPY WITH AUTOLOGOUS BLOOD STEM-CELL RESCUE FOR RELAPSED OR RESISTANT LYMPHOMA, Schweizerische medizinische Wochenschrift, 128(40), 1998, pp. 1500-1507
CISPLATIN, ETOPOSIDE AND BLEOMYCIN INFUSION (PEBI REGIMEN) IN GOOD-RISK PATIENTS WITH GERM-CELL TUMORS
Authors: COLLEONI M GRAFFEO R MARTINELLI G GHIELMINI M DEBRAUD P ZAMPINO G MARINI G CAVALLI F GOLDHIRSCH A
Citation: M. Colleoni et al., CISPLATIN, ETOPOSIDE AND BLEOMYCIN INFUSION (PEBI REGIMEN) IN GOOD-RISK PATIENTS WITH GERM-CELL TUMORS, Oncology Reports, 4(5), 1997, pp. 913-916
CISPLATIN, ETOPOSIDE AND BLEOMYCIN INFUSION (PEBI REGIMEN) IN GOOD-RISK PATIENTS WITH GERM-CELL TUMORS
Authors: COLLEONI M GRAFFEO R MARTINELLI G GHIELMINI M MARINI G CAVALLI F GOLDHIRSCH A
Citation: M. Colleoni et al., CISPLATIN, ETOPOSIDE AND BLEOMYCIN INFUSION (PEBI REGIMEN) IN GOOD-RISK PATIENTS WITH GERM-CELL TUMORS, European journal of cancer, 33, 1997, pp. 176-176
SCHEDULE-DEPENDENT MYELOTOXICITY INDUCED IN-VITRO BY THE NEW MARINE DERIVED MINOR-GROOVE INTERACTING AGENT ECTEINASCIDIN-743
Authors: GHIELMINI M COLLI E JIMENO J FAIRCLOTH G SESSA C
Citation: M. Ghielmini et al., SCHEDULE-DEPENDENT MYELOTOXICITY INDUCED IN-VITRO BY THE NEW MARINE DERIVED MINOR-GROOVE INTERACTING AGENT ECTEINASCIDIN-743, European journal of cancer, 33, 1997, pp. 807-807
CLINICAL MANIFESTATION OF SEVERE HYPERAMMONEMIA IN PATIENTS WITH MULTIPLE-MYELOMA
Authors: MARTINELLI G PECCATORI F ULLRICH B GHIELMINI M ROGGERO E GOLDHIRSCH A
Citation: G. Martinelli et al., CLINICAL MANIFESTATION OF SEVERE HYPERAMMONEMIA IN PATIENTS WITH MULTIPLE-MYELOMA, Annals of oncology, 8(8), 1997, pp. 811-811
TRANSPLANTATION OF AUTOLOGOUS BLOOD STEM-CELLS AFTER HIGH-DOSE SEQUENTIAL CHEMOTHERAPY FOR LYMPHOMA REPOPULATES THE BONE-MARROW TO A MINIMAL PROPORTION OF THE ORIGINAL STEM-CELL CONTENT
Authors: GHIELMINI M MARANGONI G CAVALLI F
Citation: M. Ghielmini et al., TRANSPLANTATION OF AUTOLOGOUS BLOOD STEM-CELLS AFTER HIGH-DOSE SEQUENTIAL CHEMOTHERAPY FOR LYMPHOMA REPOPULATES THE BONE-MARROW TO A MINIMAL PROPORTION OF THE ORIGINAL STEM-CELL CONTENT, Experimental hematology, 25(8), 1997, pp. 279-279
HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM-CELL TRANSPLANTATION IS FEASIBLE AND SAFE IN A REGIONAL-HOSPITAL - A 6-YEAR EXPERIENCE IN SOUTHERN SWITZERLAND
Authors: REGAZZONI S MARINI G GROB A PEDRAZZINI A GOLDHIRSCH A CASTELLI D CAVALLI F GHIELMINI M
Citation: S. Regazzoni et al., HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM-CELL TRANSPLANTATION IS FEASIBLE AND SAFE IN A REGIONAL-HOSPITAL - A 6-YEAR EXPERIENCE IN SOUTHERN SWITZERLAND, Bone marrow transplantation, 19(1), 1997, pp. 3-7
ESTIMATION OF THE HEMATOLOGICAL TOXICITY OF MINOR-GROOVE ALKYLATORS USING TESTS ON HUMAN CORD-BLOOD CELLS
Authors: GHIELMINI M BOSSHARD G CAPOLONGO L GERONI MC PESENTI E TORRI T DINCALCI M CAVALLI F SESSA C
Citation: M. Ghielmini et al., ESTIMATION OF THE HEMATOLOGICAL TOXICITY OF MINOR-GROOVE ALKYLATORS USING TESTS ON HUMAN CORD-BLOOD CELLS, British Journal of Cancer, 75(6), 1997, pp. 878-883
THE LAST 3 MONTHS OF LIFE OF CANCER-PATIENTS - MEDICAL ASPECTS AND ROLE OF HOME-CARE SERVICES IN SOUTHERN SWITZERLAND
Authors: SESSA C ROGGERO E PAMPALLONA S REGAZZONI S GHIELMINI M LANG M MARX B NEUENSCHWANDER H PAGANI O VASILIEVIC V CAVALLI F
Citation: C. Sessa et al., THE LAST 3 MONTHS OF LIFE OF CANCER-PATIENTS - MEDICAL ASPECTS AND ROLE OF HOME-CARE SERVICES IN SOUTHERN SWITZERLAND, Supportive care in cancer, 4(3), 1996, pp. 180-185
BONE-MARROW PARAMETERS ASSOCIATED WITH PROGENITOR-CELL MOBILIZATION IN PATIENTS WITH RELAPSED LYMPHOMA
Authors: GHIELMINI M MARANGONI G CAVALLI F
Citation: M. Ghielmini et al., BONE-MARROW PARAMETERS ASSOCIATED WITH PROGENITOR-CELL MOBILIZATION IN PATIENTS WITH RELAPSED LYMPHOMA, Experimental hematology, 24(9), 1996, pp. 612-612
MOBILIZATION AND TRANSPLANTATION OF AUTOL OGOUS HEMATOPOIETIC STEM AND PROGENITOR CELLS FROM THE BLOOD
Authors: GHIELMINI M TOBLER A
Citation: M. Ghielmini et A. Tobler, MOBILIZATION AND TRANSPLANTATION OF AUTOL OGOUS HEMATOPOIETIC STEM AND PROGENITOR CELLS FROM THE BLOOD, Schweizerische medizinische Wochenschrift, 126(9), 1996, pp. 348-356
PARAPLEGIA FOLLOWING INTRATHECAL CHEMOTHE RAPY
Authors: BERETTA F SANNA P GHIELMINI M MARINI G CAVALLI F
Citation: F. Beretta et al., PARAPLEGIA FOLLOWING INTRATHECAL CHEMOTHE RAPY, Schweizerische medizinische Wochenschrift, 126(25), 1996, pp. 1107-1111
THE EFFECT OF THE GM-CSF IL-3 FUSION PROTEIN PIXY321 ON BONE-MARROW AND CIRCULATING HEMATOPOIETIC-CELLS OF PREVIOUSLY UNTREATED PATIENTS WITH CANCER/
Authors: GHIELMINI M PETTENGELL R COUTINHO LH TESTA N CROWTHER D
Citation: M. Ghielmini et al., THE EFFECT OF THE GM-CSF IL-3 FUSION PROTEIN PIXY321 ON BONE-MARROW AND CIRCULATING HEMATOPOIETIC-CELLS OF PREVIOUSLY UNTREATED PATIENTS WITH CANCER/, British Journal of Haematology, 93(1), 1996, pp. 6-12
3RD INTERNATIONAL-SYMPOSIUM ON RECENT ADVANCES IN HEMATOPOIETIC STEM-CELL TRANSPLANTATION
Authors: GHIELMINI M
Citation: M. Ghielmini, 3RD INTERNATIONAL-SYMPOSIUM ON RECENT ADVANCES IN HEMATOPOIETIC STEM-CELL TRANSPLANTATION, Annals of oncology, 6(6), 1995, pp. 533-536
TIME-COURSE OF THE RECOVERY OF CELLULAR IMMUNE FUNCTION AFTER HIGH-DOSE CHEMOTHERAPY AND PERIPHERAL-BLOOD PROGENITOR-CELL TRANSPLANTATION FOR HIGH-GRADE NON-HODGKINS-LYMPHOMA
Authors: SCHEID C PETTENGELL R GHIELMINI M RADFORD JA MORGENSTERN GR STERN PL CROWTHER D
Citation: C. Scheid et al., TIME-COURSE OF THE RECOVERY OF CELLULAR IMMUNE FUNCTION AFTER HIGH-DOSE CHEMOTHERAPY AND PERIPHERAL-BLOOD PROGENITOR-CELL TRANSPLANTATION FOR HIGH-GRADE NON-HODGKINS-LYMPHOMA, Bone marrow transplantation, 15(6), 1995, pp. 901-906
Risultati: 1-25 | 26-28